Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

and thank you for joining the Zarius RFRMA second quarter 2025 earnings conference call. My name is Sammy, and I'll be coordinating your call today. During the presentation, you can register a question by pressing star followed by one on your telephone keypad. If you change your mind, please press star followed by two on your telephone keypad to remove yourself from the question queue. I'll now hand over to your host, Allison Way, Senior Vice President of Investor Relations and Corporate Communications to begin. Please go ahead, Allison. Thank you, Sammy. Good morning, everyone, and thank you for joining our call today. I'm joined with John Shannon, our CEO, and Steve Piper, our CFO. Earlier this morning, we issued a press release with our detailed results, which can be found on our website. After our prepared remarks, we will open the lines for questions. Before we would begin, I'd like to remind you that this call will contain forward-looking statements concerning the company's future expectations, plans, projects, and financial performance. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those forward-looking statements. For more information on a risk, please refer to our earnings release and the risk factors included in our FTC filing. Any forward-looking statements in this call represent our views only as the date of this call, and subject to applicable law, we disclaim any obligation to update such statements. Please note some metrics we will discuss today represented in a non-GAAP basis. We've reconciled the comparable GAAP and non-GAAP figures in our press release. Please let me pass the call over to John for his opening remarks. Thanks, Allison, and good morning, everyone. I'm excite...